Portal vein resection during pancreaticoduodenectomy for pancreatic neuroendocrine tumors. An international multicenter comparative study

Background The role of portal vein resection for pancreatic cancer is well established but not neuroendocrine neoplasms. Evidence from studies providing information on long-term outcome after venous in neoplasms patients lacking. Methods This a multicenter retrospective cohort study comparing pancreaticoduodenectomy with standard primary endpoint was to evaluate the survival both groups. Progression-free and overall were calculated using method Kaplan Meier, propensity score-matched analysis subsequently performed remove selection bias improve homogeneity. secondary Clavien-Dindo ?3. Results Sixty-one (11%) underwent 480 pancreaticoduodenectomy. Five (1%) perioperative deaths recorded group, postoperative clinically relevant morbidity rates similar 2 groups (pancreaticoduodenectomy 48% vs 33%). In initial analysis, associated worse 3-year progression-free (48% 83% pancreaticoduodenectomy; P < .01) 5-year (67% 91% pancreaticoduodenectomy). After score matching, no significant difference found (49% 59% = .14) (71% 69% .98). Conclusion demonstrates risk between resection. Tumor involvement superior mesenteric/portal axis should preclude surgical locally advanced